Lipocalin 2 as a clinical significance in rheumatoid arthritis

dc.contributor.authorGulkesen, Arif
dc.contributor.authorAkgol, Gurkan
dc.contributor.authorPoyraz, Ahmet K.
dc.contributor.authorAydin, Suleyman
dc.contributor.authorDenk, Affan
dc.contributor.authorYildirim, Tulay
dc.contributor.authorKaya, Arzu
dc.date.accessioned2026-08-12T17:04:54Z
dc.date.issued2017
dc.departmentFırat Üniversitesi
dc.description.abstractAim of the study: In this study, serum lipokalin 2 (LCN-2) levels and its clinical and radiological significance in patients with rheumatoid arthritis was evaluated. Material and methods: The study enrolled 37 patients with RA and 34 healthy controls. Serum LCN-2 level was measured using ELISA method. Patients with DAS 28 scores <= 3.2, and > 3.2 were allocated into lower and high/moderate disease activity groups, respectively. Additionally patients were divided into 2 groups as early RA (disease duration <= 2 years) and established RA (duration of the disease >= 2 years). Functional disability was evaluated using Health Assessment Questionnaire (HAQ). Radiographs were scored using the modified Larsen score. Results: Serum LCN-2 (p = 0.029) levels were significantly higher in patients with RA than in the controls. Serum LCN-2 level did not correlate with laboratory and clinical parameters of disease activity like erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), DAS 28, Health Assessment Questionnaire Score (HAQ) and Nottingham Health Profile (NHP). Similarly, any correlation could not be found between structural joint damage and serum LCN2 levels. Conclusions: These results indicate that serum LCN-2 levels may be used as an indicator for structural damage like erosions in the early stage of the disease but do not able to be used to monitor disease activity.
dc.identifier.doi10.5114/ceji.2017.70969
dc.identifier.endpage273
dc.identifier.issn1426-3912
dc.identifier.issn1644-4124
dc.identifier.issue3
dc.identifier.orcid0000-0001-8992-1743
dc.identifier.pmid29204091
dc.identifier.scopus2-s2.0-85032822018
dc.identifier.scopusqualityQ3
dc.identifier.startpage269
dc.identifier.urihttps://doi.org/10.5114/ceji.2017.70969
dc.identifier.urihttps://hdl.handle.net/11508/48907
dc.identifier.volume42
dc.identifier.wosWOS:000415131100007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTermedia Publishing House Ltd
dc.relation.ispartofCentral European Journal of Immunology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectrheumatoid arthritis
dc.subjectdisease activity
dc.subjectlipokalin 2
dc.subjectmodified Larsen score
dc.titleLipocalin 2 as a clinical significance in rheumatoid arthritis
dc.typeArticle

Dosyalar